Anixa Biosciences (ANIX) announced that it has completed the transfer of the Investigational New Drug application, IND, for its breast cancer vaccine from Cleveland Clinic. Anixa is now the trial sponsor for future development of its breast cancer vaccine. The transfer of the IND is a natural and planned step in the progression of the vaccine’s development. With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full sponsorship of the IND. Anixa plans to utilize multiple clinical sites, including Cleveland Clinic, for the Phase 2 and other clinical trials.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences Reports Positive Phase 1 Trial Results
- Anixa Biosciences says all primary endpoints met in breast cancer vaccine trial
- Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name
- Anixa Biosciences awarded patent covering breast cancer vaccine technology
- Anixa Biosciences executes data transfer with Cleveland Clinic